CYTEK BIOSCIENCES INC (CTKB)
Health Care · Spectral flow cytometry and cell analysis instrumentation · NASDAQ
Cytek Biosciences sells spectral flow cytometry instruments and integrated cell analysis platforms powered by patented Full Spectrum Profiling technology that enable high-resolution, high-dimensional single-cell analysis for biomedical research and clinical applications.
What CYTEK BIOSCIENCES INC does
Cytek Biosciences is a leading cell analysis solutions company that develops and commercializes instruments, reagents, software, and services for single-cell analysis. The company's proprietary Full Spectrum Profiling (FSP) technology leverages the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells with high sensitivity and dimensional depth. The company sells its cell analyzers (Aurora, Northern Lights, Aurora Evo, Aurora CS sorter) and integrated platform solutions globally to pharmaceutical, biopharma, academic research, and contract research organization customers.
Themes: Flow cytometry / cell analysis, Single-cell analysis, High-dimensional cell profiling, Biomedical research tools, Immunology and oncology applications, Clinical diagnostics, Cell sorting and isolation
Fundamentals
- Price$4.81 as of 2026-08-21 close
- Market cap$625M as of 2026-08-21
- 1-year return+20.0% 2025-08-21 close $4.01 → 2026-08-21 close $4.81
- P/En/a negative earnings
- Net margin-39.0% as of 2026-08-24
- Gross margin+53.2% as of 2026-08-24
- ROE-23.5% as of 2026-08-24
- Debt / equity0.03 as of 2026-08-24
- Revenue growth (YoY)+5.4% as of 2026-08-24
- Revenue CAGR (3y)+7.1% SEC XBRL
- Beta1.21 as of 2026-08-24
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How CTKB compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How CYTEK BIOSCIENCES INC looks technically
CYTEK BIOSCIENCES INC (CTKB) is trading 4.5% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed below its 200-day average about 68 trading days ago — a "death cross", a bearish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 22 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 61, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 9 trading days ago (its momentum flipped positive). It made a new 20-day high about 7 trading days ago. It is 22.2% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 4.5% above its 200-day average, the long-term trend line — a longer-term uptrend | +4.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $4.43 | $4.43 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $4.60 | $4.60 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 68 trading days ago — a "death cross", a bearish long-term signal | 68 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 4.5% above | +4.5% |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 22 (a reading of 25+ marks a strong trend) | 22.0 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 61, neither overbought (above 70) nor oversold (below 30) | 60.8 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($4.04 to $4.93) — its "stochastic" reading is 86 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 86.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 9 trading days ago (its momentum flipped positive) | 9 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $6.18 | $6.18 |
|---|---|---|
| From the 52-week high | it is 22.2% below its 52-week high (its highest price of the past year) | -22.2% |
| Above the 52-week low | it is 46.6% above its 52-week low (its lowest price of the past year) | +46.6% |
| Below the 52-week high | it is 22.2% below its highest point of the past year | 22.2% |
| Since a 20-day breakout | it made a new 20-day high about 7 trading days ago | 7 sessions |
| Since a 55-day breakout | it made a new 55-day high about 7 trading days ago | 7 sessions |
| All-time high | its highest closing price on record is $28.69 (set on 2021-09-15) | $28.69 |
| Given back of the 52-week move | over the past year its closes ranged ($3.35 to $5.88), and it has recovered a bit over half of its fall from last year’s high — 58% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $4.92 to $5.00. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 57.6% |
| From the all-time high | it is 83.2% below its all-time high | -83.2% |
| Nearest price level | it is sitting right on a support level at $4.79 — a price it turned at twice since 2024-10-10, most recently on 2026-07-16. Since 2024-08-21 it has 9 such levels below the current price and 4 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.3% |
| All-time low | its lowest closing price on record is $2.37 (set on 2025-05-23) | $2.37 |
| Above the all-time low | it is 103.0% above its all-time low | +103.0% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 64th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.2142 between its high and its low — about 4.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.2142 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $4.04 and $4.99 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $4.04 – $4.51 – $4.99 |
| Typical daily range (% of price) | its price moves about 4.5% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.5% |
| Stretch from the 200-day average | it is trading 1.0 daily range above its 200-day average price (4.5% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.0 daily range above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.01× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Price gaps
2
| Gap at the open | it opened on 2026-08-21 0.6% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.6% |
|---|---|---|
| Gap filled | a 2.7% gap up opened on 2026-08-10 has been "filled" 9 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 9 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 2.9 percentage points (the stock gained 5.3% while the market gained 2.3%) | +2.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 18.4 percentage points (the stock gained 21.5% while the market gained 3.1%) | +18.4% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 2.5 percentage points (the stock gained 8.6% while the market gained 11.1%) | -2.5% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 0.5 percentage points (the stock gained 20.0% while the market gained 20.5%) | -0.5% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: trading above its 200-day average, MACD momentum is positive, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, lagging the market over 6 months, near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 9.3% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 5.2% of the share price. | +9.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 10% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $4.37 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | +10.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 5% above the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $4.59 — a volume-weighted average of daily closes over 13 sessions, not a true tick-by-tick VWAP. | +4.7% |
Price levels it has turned at before
CTKB last closed at $4.81 on 2026-08-21. Since 2024-08-21 it has turned at 9 prices below its last close and 4 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $4.79 | Support | 0.3% below the last close | turned there twice · 2024-10-10 to 2026-07-16 |
| $4.72 | Support | 1.9% below the last close | turned there five times · 2024-09-12 to 2026-07-06 |
| $4.91 | Resistance | 2.0% above the last close | turned there four times · 2025-01-31 to 2026-08-14 |
| $4.59 | Support | 4.6% below the last close | turned there three times · 2025-03-10 to 2026-03-03 |
| $5.19 | Resistance | 8.0% above the last close | turned there twice · 2024-09-04 to 2025-12-22 |
| $5.69 | Resistance | 18.3% above the last close | turned there three times · 2024-09-30 to 2025-02-07 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · Pulled back from the 12-month high · At the top of its 14-day range (stochastic above 80) · Trading above the Ichimoku cloud · Near a support level (sitting on a price it has bounced off before) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.25 mean, 1=Strong Buy…5=Strong Sell) — 4 analysts
- Mean price target$5.56 range $4.75 – $7.50; median $5.00
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Key risks (from latest filing)
["Company is unprofitable with negative 36.25% net margin and may require continued investment in R&D, commercial infrastructure, and sales expansion to achieve profitability.","Revenues are growing slowly (3.61% YoY) and net losses widened in Q1 2026 ($18.9M) versus prior year ($11.4M), indicating margin pressure and execution challenges.","Competition from established cell analysis technology providers using conventional flow cytometry, mass cytometry, and other spectral flow cytometry approaches that may have greater market penetration, installed base, or resources."]
What changed in the latest 10-Q
AI-assisted comparison of CTKB's 10-Q filed 2026-05-07 against the prior one filed 2025-11-05.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to Annual Report on Form 10-K filed February 26, 2026 (newer filing) versus February 28, 2025 (older filing)
- Three months ended March 31, 2026 revenue of $44.1 million compared to March 31, 2025 revenue of $41.5 million (6% increase)
- Direct sales revenue 69% of total for Q1 2026 versus 72% for Q1 2025; distributor revenue 31% for Q1 2026 versus 28% for Q1 2025
- R&D expenses of $9.6 million for Q1 2026 versus $9.7 million for Q1 2025
- Sales and marketing expenses of $11.6 million for Q1 2026 versus $12.5 million for Q1 2025
- Net loss of $18.9 million for Q1 2026 versus $11.4 million for Q1 2025
- Statement that net loss change 'resulted primarily from a slight increase in revenues and gross profit, offset by higher operating expenses'
- Section on 'Key factors affecting our results of operations and future performance' with subsections on 'Global customer adoption' and 'Recurring revenues'
- Removed:
- Reference to year ended December 31, 2024 (older filing shows this date)
- Detailed description of Cytek Aurora, Northern Lights, Cytek Aurora Evo, and Cytek Aurora CS systems
- Reference to February 28, 2023 FCI Acquisition from Luminex Corporation
- Description of conventional flow and image-based flow cytometry instrumentation (FCI Products)
- Revenue figures for three and nine months ended September 30, 2025 and 2024
- Detailed regional revenue breakdown (EMEA, APAC, United States) and reasons for changes
- Comparison of direct sales percentages (72% and 73% for Sept 2025 vs 77% and 76% for Sept 2024)
- R&D expense figures for nine months ended September 30, 2025 and 2024
- Discussion of lower instrument sales to academic and government customers in EMEA
- Reworded:
- Overview section removes description of specific instrument models and FCI Business acquisition details, focusing instead on general platform description
- Change from comparing nine-month periods (September 30) to comparing three-month periods (March 31)
- Net loss explanation changed from discussing regional sales variations to discussing overall revenue and expense trends
- Sales and marketing expenses stated as $11.6 million and $12.5 million (Q1 comparison) versus $9.0 million and $27.5 million figures (nine-month comparison in older filing)
- Notes:
- Newer filing text appears truncated at end of 'Recurring revenues' section ('we expect recurring revenue on an absolute basis to increase and bec'), making complete comparison of that section impossible
- Older filing text also appears truncated ('We expect to continue to invest in our commercial infrastructure through hiring add'), limiting full comparison of that section
Risk Factors
- Added:
- Newer filing (2026-05-07) includes 'contract research organizations ("CROs")' terminology in the summary risk factors, whereas older filing (2025-11-05) used 'clinical research organizations ("CROs")'.
- Removed:
- Older filing (2025-11-05) included specific reference to 'our agreement with Coherent NA, Inc. and certain of its affiliates (collectively, "Coherent")' in the supplier risk factor; this reference is removed in newer filing (2026-05-07).
- Older filing (2025-11-05) contained a separate risk factor 'Our future success depends on our ability to develop and successfully introduce new and enhanced products that meet the needs of our customers'; this is removed in newer filing (2026-05-07).
- Older filing (2025-11-05) contained a separate risk factor 'New product development involves a lengthy and complex process, and we may be unable to develop or commercialize products on a timely basis, or at all'; this is removed in newer filing (2026-05-07).
- Older filing (2025-11-05) contained a separate risk factor 'If we are unable to expand or leverage the number of peer-reviewed articles published using data generated by our products or otherwise increase brand awareness, the demand for our products and our business may be adversely affected'; this is removed in newer filing (2026-05-07).
- Older filing (2025-11-05) contained language 'We have identified material weaknesses in our internal control over financial reporting. If we are unable to remediate these material weaknesses, or if we identify additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls'; newer filing (2026-05-07) simplifies to 'If we fail to maintain an effective system of internal controls'.
- Reworded:
- Product listing order changed: older filing lists 'Cytek Aurora, Cytek Aurora Evo, Northern Lights and Cytek Aurora cell sorter'; newer filing lists 'Cytek Aurora, Northern Lights, Cytek Aurora cell sorter, and Cytek Aurora Evo'.
- Supplier risk factor wording simplified: older filing states 'and, other than our agreement with Coherent NA, Inc. and certain of its affiliates (collectively, "Coherent"), we do not currently have long-term supply contracts with our sole and single source suppliers of key components'; newer filing removes this clause entirely.
- Product development risk factor consolidated: older filing had separate bullet points for 'Our future success depends on our ability to develop and successfully introduce new and enhanced products' and 'If we are unable to successfully develop new products, adapt to rapid and significant technological change...'; newer filing combines concept into single bullet without the separate introductory statement.
- Notes:
- Both filings appear truncated at the end of the provided text, so later risk factors cannot be fully compared.
- The newer filing provided text ends mid-sentence regarding FDA regulation, limiting complete assessment of that risk factor section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for CTKB — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding CTKB as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 22,573,995
- Reported value $98,648,358
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
CTKB had 4,895,239 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
CTKB had 3.77% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 7.46 days to cover at the same settlement.
- Reported short interest (shares) 4,895,239
- Short interest (% of shares outstanding) 3.77%
- Prior settlement (shares) 5,029,578
- Reported change -2.67%
- Days to cover (reported) 7.46
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Becton Dickinson (BDX)
- Thermo Fisher Scientific (TMO)
- Danaher Corporation (DHR)
- Bio-Rad Laboratories (BIO)
- Sony Group (SONY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CTKB vs…
CYTEK BIOSCIENCES INC is found in…
Frequently asked questions
What does CYTEK BIOSCIENCES INC (CTKB) do?
Cytek Biosciences is a leading cell analysis solutions company that develops and commercializes instruments, reagents, software, and services for single-cell analysis. The company's proprietary Full Spectrum Profiling (FSP) technology leverages the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells with high sensitivity and dimensional depth.
What sector is CYTEK BIOSCIENCES INC (CTKB) in?
CYTEK BIOSCIENCES INC (CTKB) is classified in the Health Care sector. Its industry is Spectral flow cytometry and cell analysis instrumentation. It trades on NASDAQ.
Who are CYTEK BIOSCIENCES INC's (CTKB) competitors?
Notable peers of CYTEK BIOSCIENCES INC (CTKB) include Becton Dickinson, Thermo Fisher Scientific, Danaher Corporation, Bio-Rad Laboratories and Sony Group. This peer set is informational only — not financial advice.
Is CYTEK BIOSCIENCES INC (CTKB) overbought or oversold right now?
CYTEK BIOSCIENCES INC (CTKB) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 61, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CTKB come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.